Wednesday, July 8, 2026
🇺🇸 FDA

pharma · No medical condition. · Breast cancer

George Institute for

The George Institute

George Institute for clinical programs — 406 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

George Institute for projects

406 ClinicalTrials.gov programs sponsored by George Institute for.

George Institute for has 406 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

406 programs

Clinical programs

Page 1 of 9

  1. 042011

    The George Institute

    Langerhans Cell Histiocytosis

    phase 3 small molecule active

    1 trial

  2. 11C-SB207145, 11C-DASB

    The George Institute

    Parkinson's disease, Prodromal phase of Parkinson's disease

    phase 3 small molecule active

    1 trial

  3. 18F-AV-1451

    The George Institute

    Maladie d' Alzheimer, Alzheimer's pathology

    phase 3 small molecule active

    1 trial

  4. 18F-LBT-999

    The George Institute

    Comatose Traumatic Brain Injury patients

    phase 3 small molecule active

    1 trial

  5. 2019/2894

    The George Institute

    Patients with High Risk Neuroblastoma

    phase 3 small molecule active

    1 trial

  6. 2021/3336

    The George Institute

    Maintenance treatment in metastatic non-squamous lung cancer

    phase 3 other active

    1 trial

  7. 2023/3720 UMBRELLA

    The George Institute

    patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment

    phase 3 small molecule active

    1 trial

  8. 2023/3764

    The George Institute

    Metastatic renal cell carcinoma (mRCC)

    phase 3 small molecule active

    1 trial

  9. 2024/4031

    The George Institute

    Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.

    phase 3 small molecule active

    1 trial

  10. 6% Hydroxy-ethyl starch (130/0.4)

    The George Institute

    Intensive Care

    phase 3 small molecule completed

    1 trial

  11. A021502

    The George Institute

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  12. ABC-HCC

    The George Institute

    intermediate-stage hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  13. AG120-C-009

    The George Institute

    Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

    phase 3 small molecule active

    1 trial

  14. AG881-C-004

    The George Institute

    Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

    phase 3 small molecule active

    1 trial

  15. ALL SCTped FORUM

    The George Institute

    Acute Lymphoblastic Leukaemia

    phase 3 small molecule active

    1 trial

  16. Afinitor 2.5 mg tablets, Afinitor 10 mg tablets

    The George Institute

    Children, adolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive

    phase 3 small molecule active

    1 trial

  17. BAZOOKA_221

    The George Institute

    Rabies infection/prophylaxis

    phase 3 small molecule active

    1 trial

  18. BuS2020

    The George Institute

    Bronchopulmonary dysplasia, Preterm newborns ≤32 weeks of gestational age.

    phase 3 small molecule active

    1 trial

  19. C16-40

    The George Institute

    Unresectable locally advanced and/or metastatic soft-tissue sarcoma

    phase 3 small molecule active

    1 trial

  20. C24-50

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  21. CL3-95005-006

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  22. CL3-95031-007

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  23. COBALAMIN

    The George Institute

    Hydroxycobalamin deficiency

    phase 3 small molecule active

    1 trial

  24. CONDROSULF 800 mg tabletta

    The George Institute

    Knee osteoarthritis with moderate to severe pain

    phase 3 small molecule active

    1 trial

  25. CSET 2021/3373

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  26. CSET 2021/3373

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  27. CSET 2023/3603

    The George Institute

    Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases

    phase 3 small molecule active

    1 trial

  28. CSET 2025/4132

    The George Institute

    Acute Myeloid Leukemia, ONCOLOGY

    phase 3 small molecule active

    1 trial

  29. CSET N° 2023/3729

    The George Institute

    Synchronous oligometastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  30. CTO # 2095

    The George Institute

    Venous thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis

    phase 3 small molecule active

    1 trial

  31. Chirhostim

    The George Institute

    Pancreatic cancer, Intraductal papillary mucinous intraductal neoplasia

    phase 3 small molecule active

    1 trial

  32. Colchicine 0.5 mg

    The George Institute

    Intracerebral Hemorrhage

    phase 3 small molecule active

    1 trial

  33. DANTE/FLOT8

    The George Institute

    locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach

    phase 3 small molecule active

    1 trial

  34. Doxy-WISE

    The George Institute

    Sexually Transmitted Infections

    phase 3 small molecule active

    1 trial

  35. EstroTep 500 MBq/mL, solution injectable

    The George Institute

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  36. FLUDEX

    The George Institute

    Severe Influenza

    phase 3 small molecule active

    1 trial

  37. Grafalon 20 mg/ml concentrato per soluzione per infusione

    The George Institute

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  38. HCB-ONC002

    The George Institute

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  39. IB2017-04

    The George Institute

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  40. IC 2021-07

    The George Institute

    Anaesthesia during free flap reconstruction surgery of the breast.

    phase 3 other active

    1 trial

  41. IC/LV/ACZ/PCHC

    The George Institute

    Chronic liver disease

    phase 3 small molecule active

    1 trial

  42. IIBSP-IPV-2024-178

    The George Institute

    lumbar arthrodesis

    phase 3 small molecule active

    1 trial

  43. IIBSP-OXI-2017-18

    The George Institute

    ILD

    phase 3 small molecule active

    1 trial

  44. IIBSP-PRE-2024-198

    The George Institute

    intrauterine growth restriction, preeclampsia

    phase 3 small molecule active

    1 trial

  45. IIBSP-SAV-2025-178

    The George Institute

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  46. IJB-SHAPERS-ODN-013

    The George Institute

    locally advanced rectal cancer

    phase 3 small molecule active

    1 trial

  47. IMPRIMIDO

    The George Institute

    Metilcrotonilglicinuria, biotinidasa deficit

    phase 3 small molecule active

    1 trial

  48. K-321-301

    The George Institute

    Fuchs Endothelial Corneal Dystrophy

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does George Institute for have?

406 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.